The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Low-dose selenite synergizes with KRAS inhibitor as a dual apoptotic and ferroptotic agent in lung adenocarcinoma.
 
Lok Seng Chan
No Relationships to Disclose
 
Johnson Liu
No Relationships to Disclose
 
Lili Li
Patents, Royalties, Other Intellectual Property - Tumor suppressor TET1 and uses thereof
 
Qian Tao
Patents, Royalties, Other Intellectual Property - Tumor suppressor TET1 and uses thereof
 
Tony S. K. Mok
Employment - The Chinese University of Hong Kong
Leadership - ACT Genomics-Sanomics Group; AstraZeneca; Aurora Tele-Oncology Platform; HUTCHMED; Lunit
Stock and Other Ownership Interests - ACT Genomics-Sanomics Group; Aurora Tele-Oncology Platform; HUTCHMED
Honoraria - Abbvie; ACEA Pharmaceutical Research; Alpha Biopharma; Amgen; Amoy Diagnostics; AstraZeneca; BeiGene; Berry Oncology; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; C4 Therapeutics; CStone Pharmaceuticals; Curio Science; D3; Daiichi Sankyo/UCB Japan; Eisai; Fishawack Facilitate; Gilead Sciences; Gritstone Bio; Guardant Health; InMed; Lilly; Lucence; Medscape; Merck Sharp & Dohme; Novartis; Origimed; PeerVoice; Permanyer Publications; Pfizer; Physicans' Education Resource; Prime Oncology; Research to Practice; Roche; Sanofi Aventis GmbH; Shanghai BeBirds Translation & Consulting; Suzhou Liangyihui Network Technology; Taiho Pharmaceutical; Takeda; touchIME
Consulting or Advisory Role - Abbvie; ACEA Pharmaceutical Research; Alpha Biopharma; Amgen; Amoy Diagnostics; AstraZeneca; BeiGene; Berry Oncology; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; C4 Therapeutics; CStone Pharmaceuticals; Curio Science; D3; Daiichi Sankyo/UCB Japan; Eisai; Fishawack Facilitate; G1 Therapeutics; geneDecode; Gilead Sciences; Gritstone Bio; Guardant Health; Hengrui Therapeutics; Ignyta; Incyte; Inivata; IQvia; Janssen; Lilly; Loxo; Lunit; Merck Serono; Merck Sharp & Dohme; Mirati Therapeutics; Novartis; Pfizer; Puma Biotechnology; Qiming Development (HK) Ltd.; Roche; SFJ Pharmaceuticals Group; Takeda; Vertex; Yuhan
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); G1 Therapeutics (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); SFJ Pharmaceuticals Group (Inst); Takeda (Inst); Xcovery (Inst)